Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates

Financial Performance - Harmony Biosciences reported quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.78 per share, and showing an increase from $0.20 per share a year ago, resulting in an earnings surprise of -12.82% [1] - The company posted revenues of $200.49 million for the quarter ended June 2025, which was 1.29% below the Zacks Consensus Estimate, but an increase from $172.81 million year-over-year [2] Market Performance - Harmony Biosciences shares have increased approximately 3.3% since the beginning of the year, compared to the S&P 500's gain of 7.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.83 on revenues of $219.89 million, and for the current fiscal year, it is $3.19 on revenues of $845.59 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Harmony operates, is currently in the bottom 43% of over 250 Zacks industries, which may impact the stock's performance [8]